Notably, among molecular glue drugs, CC-220, which targets IKZF1 in MM, has entered phase III clinical trials (NCT04975997),556 and CC-92480, which targets IKZF1/3 in relapsed or refractory MM, is also in phase III (NCT05552976).557 The drugs currently in phase III trials are one step away from potential clinical application, making them worthy of continued attention and anticipation. Here, IKZF1 is linked to Miyoshi myopathy.